Seattle Genetics reports more brentuximab data

Seattle Genetics Inc. (NASDAQ:SGEN) reported additional data from a pivotal Phase II trial of brentuximab vedotin to treat relapsed or refractory Hodgkin's lymphoma, showing that the compound produced complete and partial remission rates of 34% and 40%, respectively. Median duration of response was 29 weeks. Additionally, 22% of patients achieved stable disease, and tumor reductions were achieved in 94% of patients. Median overall survival has not been reached, while progression-free survival was 25 weeks. The single-arm, open-label, international trial enrolled 102 patients who previously received an autologous stem cell transplant. Data were presented at the American Society of Hematology meeting in Orlando. Seattle Genetics and partner Millennium Pharmaceuticals Inc. previously reported top-line data from the trial showing that brentuximab led to a 75% objective response rate, the primary endpoint. ...